Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
6
×
boston top stories
life sciences
national blog main
clinical trials
national top stories
biotech
boston
san diego blog main
new york blog main
san diego top stories
san francisco blog main
blueprint medicines
cancer
drugs
dyne therapeutics
fda
indiana blog main
indiana top stories
myotonic dystrophy type 1
new york top stories
rare disease drugs
roche
san francisco top stories
akcea therapeutics
ally bridge group
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
boulder/denver blog main
boulder/denver top stories
cancer drugs
capmatinib
What
drug
6
×
genetic
6
×
medicines
fda
ipo
rare
ago
approved
cancer
company
diseases
dyne
million
muscle
new
oks
raised
therapeutics
address
akcea
alnylam
amyloidosis
analysis
approval
approves
attr
available
battle
bio
biotech
biotechs
blueprint
bring
brings
carries
certain
considering
data
debilitating
deeper
Language
unset
Current search:
genetic
×
drug
×
" boston blog main "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues